Journal
MARINE DRUGS
Volume 20, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/md20010046
Keywords
cardiovascular diseases; fibrinolytic enzymes; marine microorganisms; thrombolytic activity
Categories
Funding
- Regione Veneto (Italy) POR FESR 2014-2020, 3S_4H-Safe, Smart, Sustainable Food for Health, 1.1.4. DGR [1139]
Ask authors/readers for more resources
Cardiovascular diseases are a significant global health threat, with thrombosis being one of the main causes. Fibrinolytic enzymes from marine microorganisms have potential as thrombolytic agents due to their improved pharmacological properties and fewer side effects.
Cardiovascular diseases (CVDs) have emerged as a major threat to global health resulting in a decrease in life expectancy with respect to humans. Thrombosis is one of the foremost causes of CVDs, and it is characterized by the unwanted formation of fibrin clots. Recently, microbial fibrinolytic enzymes due to their specific features have gained much more attention than conventional thrombolytic agents for the treatment of thrombosis. Marine microorganisms including bacteria and microalgae have the significant ability to produce fibrinolytic enzymes with improved pharmacological properties and lesser side effects and, hence, are considered as prospective candidates for large scale production of these enzymes. There are no studies that have evaluated the fibrinolytic potential of marine fungal-derived enzymes. The current review presents an outline regarding isolation sources, production, features, and thrombolytic potential of fibrinolytic biocatalysts from marine microorganisms identified so far.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available